BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 26568174)

  • 1. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.
    Ihaddadene R; Carrier M
    Expert Opin Drug Saf; 2016 Jan; 15(1):65-74. PubMed ID: 26568174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of anticoagulant treatment in cancer patients.
    Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
    Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients.
    Pathak R; Karmacharya P; Giri S; Poudel DR; Aryal MR; Bhatt VR; Shamoun FE; Pandit A
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):635-42. PubMed ID: 26236940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bariatric venous thromboembolism prophylaxis: an update on the literature.
    Hamadi R; Marlow CF; Nassereddine S; Taher A; Finianos A
    Expert Rev Hematol; 2019 Sep; 12(9):763-771. PubMed ID: 31219356
    [No Abstract]   [Full Text] [Related]  

  • 10. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
    Harrington DW
    Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: An observational study.
    Patanwala AE; Seaman SM; Kopp BJ; Erstad BL
    Thromb Res; 2018 Sep; 169():152-156. PubMed ID: 30071480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.
    Barsam SJ; Patel R; Arya R
    Br J Haematol; 2013 Jun; 161(6):764-77. PubMed ID: 23560605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    Walker CK; Sandmann EA; Horyna TJ; Gales MA
    Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
    Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
    Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis.
    Al Yami MS; Silva MA; Donovan JL; Kanaan AO
    J Thromb Thrombolysis; 2018 Jan; 45(1):36-47. PubMed ID: 29043538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review.
    Shaikh S; Boneva D; Hai S; McKenney M; Elkbuli A
    J Trauma Acute Care Surg; 2020 Apr; 88(4):522-535. PubMed ID: 31688792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
    Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
    Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.
    Shorr AF; Jackson WL; Sherner JH; Moores LK
    Chest; 2008 Jan; 133(1):149-55. PubMed ID: 17925410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.